WO1999017671A1 - Transmyocardial revascularization using radiofrequency energy - Google Patents

Transmyocardial revascularization using radiofrequency energy Download PDF

Info

Publication number
WO1999017671A1
WO1999017671A1 PCT/US1998/020799 US9820799W WO9917671A1 WO 1999017671 A1 WO1999017671 A1 WO 1999017671A1 US 9820799 W US9820799 W US 9820799W WO 9917671 A1 WO9917671 A1 WO 9917671A1
Authority
WO
WIPO (PCT)
Prior art keywords
energy
patient
heart
distal tip
elongated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/020799
Other languages
English (en)
French (fr)
Other versions
WO1999017671A9 (en
Inventor
Michael Aita
Carl J. Simpson
Randy J. Kesten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artivion Inc
Original Assignee
Cardiogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/942,874 external-priority patent/US6267757B1/en
Priority claimed from US09/107,077 external-priority patent/US6156031A/en
Application filed by Cardiogenesis Corp filed Critical Cardiogenesis Corp
Priority to CA002305333A priority Critical patent/CA2305333A1/en
Priority to EP98950873A priority patent/EP1018961A1/en
Priority to JP2000514573A priority patent/JP2001518345A/ja
Priority to AU96803/98A priority patent/AU9680398A/en
Publication of WO1999017671A1 publication Critical patent/WO1999017671A1/en
Publication of WO1999017671A9 publication Critical patent/WO1999017671A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14—Probes or electrodes therefor
    • A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/00234—Surgical instruments, devices or methods for minimally invasive surgery
    • A61B2017/00238—Type of minimally invasive operation
    • A61B2017/00243—Type of minimally invasive operation cardiac
    • A61B2017/00247—Making holes in the wall of the heart, e.g. laser Myocardial revascularization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00345—Vascular system
    • A61B2018/00351—Heart
    • A61B2018/00392—Transmyocardial revascularisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00696—Controlled or regulated parameters
    • A61B2018/00738—Depth, e.g. depth of ablation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00636—Sensing and controlling the application of energy
    • A61B2018/00773—Sensed parameters
    • A61B2018/00839—Bioelectrical parameters, e.g. ECG, EEG

Definitions

  • This invention is directed to the ablation or disruption of tissue in the wall of a
  • TMR transmyocardial revascularization
  • diagnostic agents to various locations in the patient's heart wall or for a variety of
  • TMR involves forming a plurality of channels in a
  • Patent 4,658,817 (Hardy). These early references describe intraoperative TMR
  • peripheral arterial system e.g., the femoral artery
  • the distal end of the optical fiber Within the left ventricle, the distal end of the optical fiber
  • the device is directed toward a desired location on the patient's endocardium and urged
  • the laser based revascularization procedure has been shown to be clinically
  • the present invention is directed to a method and system for the
  • said region with emissions of radiofrequency (RF) energy and is particularly
  • One method includes the step of inserting an elongated shaft having an RF
  • the RF energy emitter is guided to the interior of the left
  • ventricle and positioned against a desired portion of the ventricle's inner wall.
  • the RF energy emitter is activated to remove or otherwise injure tissue.
  • RF energy emitter may be advanced so as to remove tissue until a channel or
  • channel formation include fluoroscopic or ultrasonic visualization or advancing the
  • revascularization means a fixed distance.
  • penetration limitation can be
  • the RF energy emitter is repositioned against another portion of the heart wall and the process is repeated until enough channels or regions of ablated
  • tissue are formed to provide the desired revascularization.
  • tissue is ablated within
  • intervals of about one to about 500 msec and preferably about 30 to about 130
  • a radiofrequency burst may comprise a continuous emission or
  • discontinuous emission i.e. be pulsatile, and, if pulsatile, may involve a plurality or
  • train of pulses which may or may not be of the same width (duration), frequency or
  • the RF emissions are preferably controlled so that heart tissue is exposed to
  • the RF energy source generally should have
  • the channel formation or tissue disruption may be performed
  • the remainder of the procedure may be performed at a lower energy
  • RF energy transmitting member which has a proximal end, and an uninsulated distal tip configured to emit RF energy.
  • the channel formed in the heart wall preferably has an aspect ratio
  • the RF energy emitter includes
  • lumens for perfusion and aspiration to remove the particles from the patient's body are provided.
  • the RF energy emitter is configured to produce particles small enough
  • a flexible RF energy emitter is advanced through the patient's vasculature until a
  • a heart chamber such as the left ventricle.
  • RF energy transmitting member is advanced so that the uninsulated distal tip which
  • At least one burst of RF energy is emitted from the uninsulated
  • Another embodiment of the invention involves a minimally invasive approach where a small incision is made in the patient's chest and with or without the benefit
  • an elongated RF energy transmitting member is advanced into
  • the RF energy emitter preferably includes an RF energy transmitting
  • uninsulated distal tip can have a diameter of about 0.025 to about 0.2 inch (0.64-5.1
  • the distal tip may be solid or
  • the frequency of the RF current should not be less than 100 kHz and preferably is
  • the method and system of the invention effectively ablates or disturbs tissue within the patient's heart wall to revascularize the ablated region and particularly can
  • FIG. 1 is a schematic illustration of a system for revascularizing heart tissue
  • FIG. 2 is a transverse cross-section of the RF energy transmitting member of
  • FIG. 3 is a schematic illustration of the one shot shown in FIG. 1.
  • FIG. 4 is a schematic illustration of a system for generating trigger signals
  • FIG. 5 is an elevational view of a delivery system for the RF energy emitter
  • FIG. 6 is a schematic elevational view, partially in cross-section, of a human
  • FIG. 7 is a schematic longitudinal cross-sectional view of the distal portion of
  • FIGS. 8 and 9 are schematic longitudinal cross-sectional views of RF
  • FIGS. 1 and 2 depict an RF system 10 embodying features of the invention
  • the RF energy transmitting member The RF
  • energy transmitting member 11 includes an electrical conductor 14 which may be
  • a suitable insulating polymeric material is the
  • the output from the RF energy source 12 is pulsed by pulse-trigger system
  • the pulsed output signal 20 from the one-shot 17 actuates the transistor 21 for the
  • the output of the transistor 21 is connected to reed
  • the output of the reed relay 22 is connected in series to the foot switch 23.
  • FIG. 3 illustrates in more detail the one-shot shown in FIG. 1 which has 14
  • pins identified as pins a-n in FIG. 3.
  • the one-shot shown in FIG. 3 has the pins
  • the one-shot model number CD4047 has these pins numbered 1-14.
  • trigger signal 18 from an ECG unit is received by pin h and upon receipt of the
  • pin j is controlled by the resistance R and capacitance C from the RC circuit
  • the resistance R can typically range from about
  • the capacitance can typically range from about 0.08 to
  • FIG. 4 schematically illustrates a system of generating trigger signals 18
  • the signals from the patient's heart 31 are based upon the patient's heart cycle 30.
  • the signals from the patient's heart 31 are
  • trigger generating system 32 which may also be contained in the ECG unit.
  • trigger signal generating system 32 is preprogrammed to emit one or more trigger
  • FIG. 5 illustrates a system for the percutaneous
  • an RF system which has an outer catheter 40, a shaped distal end 41 , a
  • This system also includes an inner catheter
  • catheter 44 which is slidably and rotatably disposed within the inner lumen of the
  • outer catheter 40 which has a shaped distal section 45, a distal end 46, a port
  • An RF energy emitter 50 is slidably disposed within the
  • the distal section 45 of the inner catheter 44 is at an angle with respect to the main shaft section 51 of the inner catheter to orient the
  • the present invention also comprises a method for
  • An RF system 10 including
  • an elongated shaft 60 with an RF energy emitter 50 disposed at the distal end is
  • the RF energy emitter 50 is
  • the RF energy emitter 50 is activated and urged against the muscle 62 to
  • tissue forming the revascularization channel 64.
  • region disturbed or ablated should extend a desired distance through the
  • the RF energy emitter 50 is deactivated, withdrawn from channel 64 and
  • RF energy emitter 50 on the distal end is introduced through a small opening in the patient's chest wall. RF system 10 is advanced until the RF energy emitter 50 is
  • emitter 50 is activated and urged towards the muscle 62. Tissue is removed
  • channels 64 or similar revascularization sites are formed in muscle 62 to
  • the RF energy emitter 50 may be maintained in position on the RF energy emitter 50
  • the RF energy emitter 50 can be maintained in place by applying a vacuum at the
  • the operation may be synchronized
  • the RF energy emitter 50 is subject to
  • the RF energy emitter 50 may operate at two or more energy
  • the initial tissue removal to penetrate the endocardium 66 is
  • the remainder of the tissue removal may be performed at a lower energy level to
  • control lines 70 are
  • Adhesive bonding may utilize any of a variety of adhesives, including
  • control lines 70 are thus axially,
  • a mechanism such as a ring or knob may
  • control lines 70 may be attached to the proximal ends of control lines 70 to allow manipulation of control
  • Control lines 70 are preferably approximately 3-mil stainless steel wire,
  • an outer tubular member 74 preferably encloses control lines 70
  • Outer tubular member 74 is secured at
  • control lines 70 are
  • Channels 76 are preferably constructed of 30 gauge polyamide tubing.
  • Control lines 70 are thus guided to remain both separated and within well controlled
  • the positioning of the device may be viewed by esophageal ultrasound
  • trans-thoracic ultrasound imaging and trans-thoracic fluoroscopic imaging.
  • RF energy emitter 50 may
  • FIG. 8 illustrates the distal portion of an RF system
  • the thermal ablator 78 has an electrode 80
  • the diameter of probe 82 should be from about 1.0 to 5.0 mm.
  • proximal ends of the electrode 80 is are connected to a radiofrequency generating
  • Radiofrequency energy may also provide inductive heating as shown in
  • FIG. 9 The distal portion of an RF system 10 has a ferrite probe 84 on the end.
  • radiofrequency generating means (not shown) irradiates the patient's body with
  • Radiofrequency energy at a frequency to which body tissue is relatively transparent but the ferrite Radiofrequency energy may also provide inductive heating as shown in FIG. 9.
  • distal portion of an RF system 10 has a ferrite probe 84 on the end.
  • radiofrequency generating means (not shown) irradiates the patient's body with
  • Eighteen channels were made in the heart of a live, anesthetized medium
  • distal tip of the RF delivery system were varied to determine the nature of the
  • the revascularization may be performed from

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Plasma & Fusion (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgical Instruments (AREA)
PCT/US1998/020799 1997-10-02 1998-10-02 Transmyocardial revascularization using radiofrequency energy Ceased WO1999017671A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002305333A CA2305333A1 (en) 1997-10-02 1998-10-02 Transmyocardial revascularization using radiofrequency energy
EP98950873A EP1018961A1 (en) 1997-10-02 1998-10-02 Transmyocardial revascularization using radiofrequency energy
JP2000514573A JP2001518345A (ja) 1997-10-02 1998-10-02 高周波エネルギを利用した心筋血管再生術
AU96803/98A AU9680398A (en) 1997-10-02 1998-10-02 Transmyocardial revascularization using radiofrequency energy

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/942,874 US6267757B1 (en) 1995-08-09 1997-10-02 Revascularization with RF ablation
US08/942,874 1997-10-02
US94729097A 1997-10-07 1997-10-07
US08/947,290 1997-10-07
US09/107,077 US6156031A (en) 1995-08-09 1998-06-29 Transmyocardial revascularization using radiofrequency energy
US09/107,077 1998-06-29

Publications (2)

Publication Number Publication Date
WO1999017671A1 true WO1999017671A1 (en) 1999-04-15
WO1999017671A9 WO1999017671A9 (en) 1999-06-17

Family

ID=27380246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/020799 Ceased WO1999017671A1 (en) 1997-10-02 1998-10-02 Transmyocardial revascularization using radiofrequency energy

Country Status (5)

Country Link
EP (1) EP1018961A1 (enExample)
JP (1) JP2001518345A (enExample)
AU (1) AU9680398A (enExample)
CA (1) CA2305333A1 (enExample)
WO (1) WO1999017671A1 (enExample)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013641A2 (en) 2001-08-10 2003-02-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Side-exit catheter and method for its use
US6953481B2 (en) 1998-09-10 2005-10-11 Percardia, Inc. Designs for left ventricular conduit
US7294115B1 (en) 1998-01-30 2007-11-13 Percardia, Inc. Methods of providing direct blood flow between a heart chamber and a coronary vessel
US7326219B2 (en) 2002-09-09 2008-02-05 Wilk Patent Development Device for placing transmyocardial implant
EP1218801A4 (en) * 1999-09-08 2009-07-01 Mederi Therapeutics Inc SYSTEMS AND METHODS FOR MONITORING AND CONTROLLING MEDICAL DEVICES
US7704222B2 (en) 1998-09-10 2010-04-27 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US9292152B2 (en) 2009-09-22 2016-03-22 Mederi Therapeutics, Inc. Systems and methods for controlling use and operation of a family of different treatment devices
US9675403B2 (en) 2000-05-18 2017-06-13 Mederi Therapeutics, Inc. Graphical user interface for monitoring and controlling use of medical devices
US9675404B2 (en) 2009-09-22 2017-06-13 Mederi Therapeutics, Inc. Systems and methods for treating tissue with radiofrequency energy
US9750563B2 (en) 2009-09-22 2017-09-05 Mederi Therapeutics, Inc. Systems and methods for treating tissue with radiofrequency energy
US9775664B2 (en) 2009-09-22 2017-10-03 Mederi Therapeutics, Inc. Systems and methods for treating tissue with radiofrequency energy
US9925000B2 (en) 1999-09-08 2018-03-27 Mederi Therapeutics, Inc. Systems and methods for monitoring and controlling use of medical devices
US10386990B2 (en) 2009-09-22 2019-08-20 Mederi Rf, Llc Systems and methods for treating tissue with radiofrequency energy
US10993805B2 (en) 2008-02-26 2021-05-04 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US11185405B2 (en) 2013-08-30 2021-11-30 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US11337800B2 (en) 2015-05-01 2022-05-24 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US11357624B2 (en) 2007-04-13 2022-06-14 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US11517431B2 (en) 2005-01-20 2022-12-06 Jenavalve Technology, Inc. Catheter system for implantation of prosthetic heart valves
US11564794B2 (en) 2008-02-26 2023-01-31 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11589981B2 (en) 2010-05-25 2023-02-28 Jenavalve Technology, Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
US12121461B2 (en) 2015-03-20 2024-10-22 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath
US12171658B2 (en) 2022-11-09 2024-12-24 Jenavalve Technology, Inc. Catheter system for sequential deployment of an expandable implant
US12414854B2 (en) 2010-05-20 2025-09-16 Jenavalve Technology, Inc. Catheter system for introducing an expandable stent into the body of a patient
US12433745B2 (en) 2017-01-27 2025-10-07 Jenavalve Technology, Inc. Heart valve mimicry

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641610B2 (en) 1998-09-10 2003-11-04 Percardia, Inc. Valve designs for left ventricular conduits
WO2000015147A1 (en) 1998-09-10 2000-03-23 Percardia, Inc. Transmycardial shunt and its attachment mechanism, for left ventricular revascularization
US6409697B2 (en) 1999-05-04 2002-06-25 Heartstent Corporation Transmyocardial implant with forward flow bias
US7033372B1 (en) 1999-08-04 2006-04-25 Percardia, Inc. Corkscrew reinforced left ventricle to coronary artery channel
EP1210024A1 (en) 1999-09-08 2002-06-05 Curon Medical, Inc. System for controlling a family of treatment devices
US6854467B2 (en) 2000-05-04 2005-02-15 Percardia, Inc. Methods and devices for delivering a ventricular stent
US6976990B2 (en) 2001-01-25 2005-12-20 Percardia, Inc. Intravascular ventriculocoronary bypass via a septal passageway
US6949118B2 (en) 2002-01-16 2005-09-27 Percardia, Inc. Encased implant and methods
US7008397B2 (en) 2002-02-13 2006-03-07 Percardia, Inc. Cardiac implant and methods
CN103037792B (zh) * 2010-07-30 2016-07-13 Umc乌德勒支控股有限公司 发生器、发生器和导管的组合、及提供电脉冲的方法
WO2021216515A1 (en) * 2020-04-21 2021-10-28 Boston Scientific Scimed, Inc. Adaptive ecg triggering in an ablation system

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658817A (en) 1985-04-01 1987-04-21 Children's Hospital Medical Center Method and apparatus for transmyocardial revascularization using a laser
EP0553576A1 (en) * 1990-09-24 1993-08-04 Plc Medical Systems, Inc. Heart-synchronized pulsed laser system
US5389096A (en) 1990-12-18 1995-02-14 Advanced Cardiovascular Systems System and method for percutaneous myocardial revascularization
US5554152A (en) 1990-12-18 1996-09-10 Cardiogenesis Corporation Method for intra-operative myocardial revascularization
WO1996035469A1 (en) * 1995-05-10 1996-11-14 Cardiogenesis Corporation System for treating or diagnosing heart tissue
WO1996039967A1 (en) * 1995-06-07 1996-12-19 Ep Technologies, Inc. Tissue heating and ablation systems and methods which predict maximum tissue temperature
WO1997027897A1 (en) * 1996-02-02 1997-08-07 Transvascular, Inc. A device, system and method for interstitial transvascular intervention
US5672170A (en) * 1996-06-20 1997-09-30 Cynosure, Inc. Laser transmyocardial revascularization arrangement
EP0858779A1 (en) * 1997-02-03 1998-08-19 Eclipse Surgical Technologies, Inc. Transmyocardial revascularisation device
US7844393B2 (en) 2003-05-15 2010-11-30 Alpine Electronics, Inc. Vehicle navigation system and method

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658817A (en) 1985-04-01 1987-04-21 Children's Hospital Medical Center Method and apparatus for transmyocardial revascularization using a laser
EP0553576A1 (en) * 1990-09-24 1993-08-04 Plc Medical Systems, Inc. Heart-synchronized pulsed laser system
US5389096A (en) 1990-12-18 1995-02-14 Advanced Cardiovascular Systems System and method for percutaneous myocardial revascularization
US5554152A (en) 1990-12-18 1996-09-10 Cardiogenesis Corporation Method for intra-operative myocardial revascularization
WO1996035469A1 (en) * 1995-05-10 1996-11-14 Cardiogenesis Corporation System for treating or diagnosing heart tissue
WO1996039967A1 (en) * 1995-06-07 1996-12-19 Ep Technologies, Inc. Tissue heating and ablation systems and methods which predict maximum tissue temperature
WO1997027897A1 (en) * 1996-02-02 1997-08-07 Transvascular, Inc. A device, system and method for interstitial transvascular intervention
US5672170A (en) * 1996-06-20 1997-09-30 Cynosure, Inc. Laser transmyocardial revascularization arrangement
EP0858779A1 (en) * 1997-02-03 1998-08-19 Eclipse Surgical Technologies, Inc. Transmyocardial revascularisation device
US7844393B2 (en) 2003-05-15 2010-11-30 Alpine Electronics, Inc. Vehicle navigation system and method

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294115B1 (en) 1998-01-30 2007-11-13 Percardia, Inc. Methods of providing direct blood flow between a heart chamber and a coronary vessel
US7736327B2 (en) 1998-09-10 2010-06-15 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US6953481B2 (en) 1998-09-10 2005-10-11 Percardia, Inc. Designs for left ventricular conduit
US7101402B2 (en) 1998-09-10 2006-09-05 Percardia, Inc. Designs for left ventricular conduit
US8597226B2 (en) 1998-09-10 2013-12-03 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US8216174B2 (en) 1998-09-10 2012-07-10 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
US7704222B2 (en) 1998-09-10 2010-04-27 Jenavalve Technology, Inc. Methods and conduits for flowing blood from a heart chamber to a blood vessel
EP1218801A4 (en) * 1999-09-08 2009-07-01 Mederi Therapeutics Inc SYSTEMS AND METHODS FOR MONITORING AND CONTROLLING MEDICAL DEVICES
US9925000B2 (en) 1999-09-08 2018-03-27 Mederi Therapeutics, Inc. Systems and methods for monitoring and controlling use of medical devices
US8449529B2 (en) 1999-09-08 2013-05-28 Mederi Therapeutics, Inc. Systems and methods for monitoring and controlling use of medical devices
US9750559B2 (en) 1999-09-08 2017-09-05 Mederi Therapeutics Inc System and methods for monitoring and controlling use of medical devices
US9675403B2 (en) 2000-05-18 2017-06-13 Mederi Therapeutics, Inc. Graphical user interface for monitoring and controlling use of medical devices
WO2003013641A2 (en) 2001-08-10 2003-02-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Side-exit catheter and method for its use
US7326219B2 (en) 2002-09-09 2008-02-05 Wilk Patent Development Device for placing transmyocardial implant
US11517431B2 (en) 2005-01-20 2022-12-06 Jenavalve Technology, Inc. Catheter system for implantation of prosthetic heart valves
US11357624B2 (en) 2007-04-13 2022-06-14 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US12232957B2 (en) 2008-02-26 2025-02-25 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11564794B2 (en) 2008-02-26 2023-01-31 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US11154398B2 (en) 2008-02-26 2021-10-26 JenaValve Technology. Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US10993805B2 (en) 2008-02-26 2021-05-04 Jenavalve Technology, Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US10292756B2 (en) 2009-09-22 2019-05-21 Mederi Rf, Llc Systems and methods for treating tissue with radiofrequency energy
US11471214B2 (en) 2009-09-22 2022-10-18 Mederi Rf, Llc Systems and methods for treating tissue with radiofrequency energy
US9750563B2 (en) 2009-09-22 2017-09-05 Mederi Therapeutics, Inc. Systems and methods for treating tissue with radiofrequency energy
US10363089B2 (en) 2009-09-22 2019-07-30 Mederi Rf, Llc Systems and methods for treating tissue with radiofrequency energy
US10386990B2 (en) 2009-09-22 2019-08-20 Mederi Rf, Llc Systems and methods for treating tissue with radiofrequency energy
US10624690B2 (en) 2009-09-22 2020-04-21 Mederi Rf, Llc Systems and methods for controlling use and operation of a family of different treatment devices
US10639090B2 (en) 2009-09-22 2020-05-05 Mederi Rf, Llc Systems and methods for controlling use and operation of a treatment device
US9675404B2 (en) 2009-09-22 2017-06-13 Mederi Therapeutics, Inc. Systems and methods for treating tissue with radiofrequency energy
US9292152B2 (en) 2009-09-22 2016-03-22 Mederi Therapeutics, Inc. Systems and methods for controlling use and operation of a family of different treatment devices
US9513761B2 (en) 2009-09-22 2016-12-06 Mederi Therapeutics, Inc. Systems and methods for controlling use of treatment devices
US9310956B2 (en) 2009-09-22 2016-04-12 Mederi Therapeutics, Inc. Systems and methods for controlling use and operation of a family of different treatment devices
US9448681B2 (en) 2009-09-22 2016-09-20 Mederi Therapeutics, Inc. Systems and methods for controlling use and operation of a family of different treatment devices
US9495059B2 (en) 2009-09-22 2016-11-15 Mederi Therapeutics, Inc. Systems and methods for controlling use and operation of a family of different treatment devices
US9775664B2 (en) 2009-09-22 2017-10-03 Mederi Therapeutics, Inc. Systems and methods for treating tissue with radiofrequency energy
US11507247B2 (en) 2009-09-22 2022-11-22 Mederi Rf, Llc Systems and methods for treating tissue with radiofrequency energy
US12414854B2 (en) 2010-05-20 2025-09-16 Jenavalve Technology, Inc. Catheter system for introducing an expandable stent into the body of a patient
US11589981B2 (en) 2010-05-25 2023-02-28 Jenavalve Technology, Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
US12447015B2 (en) 2010-05-25 2025-10-21 Jenavalve Technology, Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
US11185405B2 (en) 2013-08-30 2021-11-30 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US12318281B2 (en) 2013-08-30 2025-06-03 Jenavalve Technology, Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
US12121461B2 (en) 2015-03-20 2024-10-22 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath
US11337800B2 (en) 2015-05-01 2022-05-24 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US12343255B2 (en) 2015-05-01 2025-07-01 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
US11065138B2 (en) 2016-05-13 2021-07-20 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US12433745B2 (en) 2017-01-27 2025-10-07 Jenavalve Technology, Inc. Heart valve mimicry
US12171658B2 (en) 2022-11-09 2024-12-24 Jenavalve Technology, Inc. Catheter system for sequential deployment of an expandable implant

Also Published As

Publication number Publication date
AU9680398A (en) 1999-04-27
WO1999017671A9 (en) 1999-06-17
EP1018961A1 (en) 2000-07-19
JP2001518345A (ja) 2001-10-16
CA2305333A1 (en) 1999-04-15

Similar Documents

Publication Publication Date Title
US6156031A (en) Transmyocardial revascularization using radiofrequency energy
WO1999017671A1 (en) Transmyocardial revascularization using radiofrequency energy
US6267757B1 (en) Revascularization with RF ablation
US5389096A (en) System and method for percutaneous myocardial revascularization
US5885272A (en) System and method for percutaneous myocardial revascularization
US7857811B2 (en) Methods and devices for ablation
US6030380A (en) Radio frequency transmyocardial revascularization
US12016619B2 (en) Transseptal crossing system for single pass large bore access
US6217576B1 (en) Catheter probe for treating focal atrial fibrillation in pulmonary veins
US5944716A (en) Radio frequency transmyocardial revascularization corer
US6589232B1 (en) Selective treatment of endocardial/myocardial boundary
US5925033A (en) Method for intra-operative myocardial revascularization
US5840075A (en) Dual laser device for transmyocardial revascularization procedures
EP1595576B1 (en) Non-contact tissue ablation device
US6971394B2 (en) Methods and devices for ablation
AU2002315167B2 (en) Methods and devices for ablation
US6231570B1 (en) Electrode catheter system for tissue ablation
US8187251B2 (en) Methods of treating cardiac arrhythmia
AU2002315167A1 (en) Methods and devices for ablation
US20020019629A1 (en) Devices, systems and methods for transluminally and controllably forming intramyocardial channels in cardiac tissue
EP1020202A2 (en) Medical device for transmyocardial revascularization
AU9409698A (en) Selective treatment of endocardial/myocardial boundary

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998950873

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2305333

Country of ref document: CA

Ref country code: CA

Ref document number: 2305333

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 514573

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998950873

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998950873

Country of ref document: EP